Multidrug resistance (MDR) in cancerMechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs

European Journal of Pharmaceutical Sciences

Volumn 11, Issue 4, 2000, Pages 265-283

  Krishna, Rajesh ^a,b   Mayer, Lawrence D ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

Canalicular multispecific organic anion transporter; Drug drug interactions; Liposomal doxorubicin; P glycoprotein; Pharmacokinetics; PSC 833

Indexed keywords

ANTIMALARIAL AGENT; ANTINEOPLASTIC AGENT; BEPRIDIL; CALCIUM ANTAGONIST; CALMODULIN INHIBITOR; CAMPTOTHECIN; CHLORAMBUCIL; CHLOROQUINE; CHLORPROMAZINE; CISPLATIN; CLOPENTHIXOL; CYCLOSPORIN A; DAUNORUBICIN; DEXVERAPAMIL; DILTIAZEM; DOXORUBICIN; ETOPOSIDE; FELODIPINE; FLUPENTIXOL; GLUCURONIC ACID; GLYCOPROTEIN P; ISRADIPINE; LIPOSOME; MITOXANTRONE; NICARDIPINE; NIFEDIPINE; PROCHLORPERAZINE; PROSTAGLANDIN DERIVATIVE; SARCOLYSIN; TIAPAMIL; TRIFLUOPERAZINE; VALSPODAR; VERLUKAST; VINBLASTINE; VINCRISTINE; VINDESINE;

ANION TRANSPORT; CANCER; DRUG INTERACTION; HUMAN; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; CALCIUM CHANNEL BLOCKERS; CYCLOSPORINS; DRUG CARRIERS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GLUTATHIONE; HUMAN; P-GLYCOPROTEIN; VERAPAMIL;

EID: 0033799839     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-0987(00)00114-7     Document Type: Review

References (262)

1. ATP-dependent S-(2,4-dinitrophenyl) glutathione transport in canalicular plasma membrane vesicles from rat liver
2. Circumvention of multiple-drug resistance in human cancer cells by thioridazine, trifluoperazine, and chlorpromazine
3. Most drugs that reverse multidrug resistance also inhibit photoaffinity labeling of P-glycoprotein by a vinblastine analog
4. In vivo reversal of doxorubicin resistance by a new tiapamil analog Ro11-2933
5. Characterization of the M(r) 190 000 multidrug resistance protein (MRP) in drug selected and transfected human tumor cell
6. Plasma concentration-response relationship of verapamil in the treatment of angina pectoris
7. The gene encoding multidrug resistance is induced and pressed at high levels during pregnancy in the secreting epithelium of the uterus
8. The biology of the bile canaliculus
9. Comparison of nitrogen-mustard-sensitive and -resistant Yoshida sarcomas
10. A 190-kilodalton protein overexpressed in non-P-glycoprotein-containing multidrug-resistant cells and its relationship to the MRP gene
11. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance
12. Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells
13. PCR gene expression analysis of multidrug resistance associated genes in primary and relapsed state leukemias: comparison of mdrl, mrp, topoisomerase IIα, topoisomerase IIβ and cyclin A mRNA levels
14. Phase I and pharmacokinetic study of D-verapamil and doxorubicin
15. Expression of human glutathione S-transferases in Saccharomyces cerevisiae confers resistance to the anticancer drugs adriamycin and chlorambucil
16. In vivo circumvention of P-glycoprotein mediated multidrug resistance of tumor cells with PSC 833
17. Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporine derivative
18. Differential inhibition by cyclosporines of primary-active ATP-dependent transporters in the hepatocyte canalicular membrane
19. ATP-dependent export pumps and their inhibition by cyclosporines
20. Phase I study of etoposide with PSC-833 as a modulator of multidrug resistance in patients with cancer
21. Effect of multidrug resistance modulators on the hepatobiliary disposition of doxorubicin in the isolated perfused rat liver
22. Do cMOAT (MRP2), other MRP homologues, and LRP play a role in MDR
23. P-Glycoprotein, multidrug resistance and tumor progression
24. Bcl-2 proto-oncogene and the gastrointestinal epithelial tumor progression model
25. Effect of GF120918, a potent multidrug resistance modulator, on the pharmacokinetics and pharmacodynamics of doxorubicin in the dog
26. Analysis of P-glycoprotein (P-gp) and non-P-gp multidrug resistance in acute myeloid leukemia
27. Analysis of the expression of multidrug resistance-associated protein (MRP) in hematological malignancies
28. Tumor sulfhydryl levels and sensitivity to the nitrogen mustard merophan
29. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cell at diagnosis
30. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy
31. Expression of the apoptosis-suppressing protein bcl-2, in neuroblastoma is associated with unfavorable histology and N-myc amplification
32. Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta
33. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma
34. Immunohistochemical detection of P-glycoprotein prognostic correlation in soft tissue sarcoma of childhood
35. Overexpression of glutathione S-transferase and elevation of thiol pools in a multidrug resistant human colon cancer cell line
36. Modulation of etoposide (VP-16) cytotoxicity by verapamil or cyclosporine in multidrug-resistant human leukemic cell lines and normal bone marrow
37. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes
38. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells
39. Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats
40. Characterization and immunological identification of cDNA clones encoding two human DNA topoisomerase II isozymes
41. Sensitization of human colon tumor xenografts to L-phenylalanine mustard using ethacrynic acid
42. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line
43. Effect of calcium antagonists on the chemosensitivity of two multidrug-resistant human tumour cell lines which do not overexpress P-glycoprotein
44. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers
45. Distribution and activity of doxorubicin combined with SDZ PSC 833 in mice with P388 and P388/DOX leukemia
46. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites
47. Membrane vesicles from multidrug-resistant human cancer cells contain a specific 150- to 170-kDa protein detected by photoaffinity labeling
48. The three mouse multidrug resistance (mdr) genes are expressed in a tissue specific manner in normal mouse tissues
49. Reversal of P-glycoprotein-mediated multidrug resistance by XR9051, a novel diketopiperazine derivative
50. Doxorubicin in combination with verapamil in advanced colorectal cancer: A phase II trial
51. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator LY335979
52. Differential amplification and disproportionate expression of five genes in three multidrug-resistant Chinese hamster lung cell lines
53. Direct correlation between DNA topoisomerase II activity and cytotoxicity in Adriamycin-sensitive and resistant P388 leukemia cell lines
54. A model for computer simulation of P-glycoprotein and transmembrane delta pH-mediated anthracycline transport in multidrug-resistant tumor cells
55. Cisplatin induces renal expression of p-glycoprotein and canalicular multispecific organic anion transporter
56. Modulation of mitomycin C-induced multidrug resistance in vitro
57. Purification of topoisomerase II from amsacrine-resistant p388 leukemia cells: Evidence for two forms of the enzyme
58. Inhibition of the multidrug transporter, P-glycoprotein, by the cyclosporine analogue PSC 833, cyclosporine, and verapamil
59. Human multi-drug-resistant cancer cells exhibit a high degree of selectivity for stereoisomers of verapamil and quinidine
60. A Phase I trial of doxorubicin (DOX) and PSC 833, a modulator of multidrug resistance (MDR)
61. Reversal of multidrug resistance
62. Effects of verapamil on the uptake and efflux of etoposide (VP16) in both sensitive and resistant cancer cells
63. Canalicular transport of reduced glutathione in normal and mutant Eisai hyperbilirubinemic rats
64. Phase I trial of taxol (T) with high dose cyclosporine (CsA) as a modulator of multidrug resistance (MDR)
65. Phase I trial of etoposide with the cyclosporine SDZ PSC 833, a modulator of multidrug resistance (MDR)
66. Bcl-2 modulation of apoptosis induced by anticancer drugs: resistance to thymidylate stress is independent of classical resistance pathways
67. Expression of a multidrug-resistance gene in human tumors and tissues
68. Amplification of the multidrug resistance gene in some chloroquine-resistant isolates of P. falciparum
69. Modulators of multidrug resistance: Preclinical studies
70. Pharmacology of drugs that alter multidrug resistance in cancer
71. Pharmacologic circumvention of multidrug resistance
72. Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance
73. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes
74. Liposome formulations with prolonged circulation time in blood enhanced uptake by tumors
75. Enhancement of sensitivity to adriamycin in resistant P388 leukemia by the calmodulin inhibitor trifluoperazine
76. Factors governing the modulation of vinca-alkaloid resistance in doxorubicin-resistant cells by the calmodulin inhibitor trifluoperazine
77. Correlation between potency of calmodulin inhibitors and effects on cellular levels and cytotoxicity activity of doxorubicin (adriamycin) in resistant P388 mouse leukemia cells
78. Structure and function of P-glycoprotein in normal liver and small intestine
79. SDZ PSC 833, a non-immunosuppressive cyclosporine analog is a very potent multidrug-resistant modifier
80. Overcoming multidrug resistance in chinese hamster ovary cells in vitro by cyclosporine A (sandimmune) and non-immunosuppressive derivatives
81. 4 receptor antagonist MK571 specifically modulates MRP associated multidrug resistance
82. P-glycoprotein in human sarcoma: evidence for multidrug resistance
83. VX-853: A novel bispecific chemosensitizer which reverses P-glycoprotein and MRP-mediated multidrug resistance
84. Phase I and pharmacokinetic study of SDZ PSC 833 per os in combination with doxorubicin in patients with solid tumors
85. Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: prognostic implications
86. Expression of a multidrug resistance gene in human tumors
87. How cancer cells evade chemotherapy: Sixteenth Richard and Hinda Rosenthal Foundation award lecture
88. Biochemistry of multidrug resistance mediated by the multidrug transporter
89. Overexpression of multidrug resistance-associated protein increases resistance to natural product drugs
90. Cloning and characterization of a second member of the mouse mdr gene family
91. Regulation of Bcl-2 oncoprotein levels with differentiation of human neuroblastoma cells
92. Co-variation of glutathione transferase expression and cytostatic drug resistance in HeLa cells: establishment of class Mu glutathione transferase M3-3 as the dominating isoenzyme
93. Verapamil-mediated sensitization of doxorubicin-selected pleiotrophic resistance in human sarcoma cells: selectivity for drugs which produce DNA scission
94. Verapamil with mitoxantrone for advanced ovarian cancer: A negative phase II trial
95. Is the multidrug transporter a flippase?
96. Stereoisomers of calcium antagonists which differ markedly in their potencies as calcium blockers are equally effective in modulating drug transport by P-glycoprotein
97. Transepithelial transport of drugs by the multidrug transporter in cultured Madin-Darby canine kidney cell epithelia
98. ATP-dependent transport of vinblastine in vesicles from human multidrug-resistant cells
99. Modulation by verapamil of vincristine pharmacokinetics and toxicity in mice bearing human tumor xenografts
100. Failure of liposomal encapsulation of doxorubicin to circumvent multidrug resistance in an in vitro model of rat glioblastoma cells
101. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma
102. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative
103. Active efflux of daunorubicin and adriamycin in sensitive and resistant sublines of P388 leukemia
104. The ATP dependent glutathione S-conjugate export pump
105. ATP-dependent primary active transport of cysteinyl leukotrienes across liver canalicular membrane. Role of the ATP-dependent transport system for glutathione S-conjugates
106. Transport of molecules in the tumour interstitium: a review
107. Determinants of tumor blood flow: a review
108. ATP-dependent transporter of glutathione S-conjugates by the multidrug resistance-associated protein
109. Cyclosporin A treatment induces overexpression of P-glycoprotein in the kidney and other tissues
110. SKF10864, a water-soluble analog of camptothecin with broad-spectrum activity in preclinical tumor models
111. SDZ PSC 833 - a novel potent in vitro chemosensitizer in multiple myeloma
112. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
113. Overexpression of P-glycoprotein and alterations in topoisomerase II in p388 mouse leukemia cells selected in vivo for resistance to mitoxantrone
114. The function of GP170, the multidrug resistance gene product, in rat liver canalicular membrane vesicles
115. Low bioavailability of cyclosporine microemulsion and tacrolimus in a small bowel transplant recipient: possible relationship to intestinal p-glycoprotein activity
116. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines
117. Induction of cMrp/cMoat gene expression by cisplatin, 2-acetylaminofluorene, or cycloheximide in rat hepatocytes
118. SDZ P.S.C. 833, a non-immunosuppressive cyclosporine: Its potency in overcoming P-glycoprotein mediated multidrug resistance of murine leukemia
119. Leukotrienes: Biosynthesis, transport, inactivation, and analysis
120. The function of the multidrug resistance proteins (MRP and cMRP) in drug conjugate transport and hepatobiliary excretion
121. Promotion of daunorubicin uptake and toxicity by the calcium antagonist tiapamil and its analogs
122. Glutathione S-transferases and protection against oxidative stress
123. Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice
124. Defective ATP-dependent bile canalicular transport of organic anions in mutant (TR-) rats with conjugated hyperbilirubinemia
125. cDNA cloning and inducible expression of human multidrug resistance associated protein 3 (MRP3)
126. Resistance to anthrapyrazoles and anthracyclines in multidrug-resistant P388 murine leukemia cells: reversal by calcium blockers and calmodulin antagonists
127. The contribution of the MRP (multidrug resistance protein) family to drug resistance
128. Evaluation of three established cell lines derived from patients with prostate cancer (DU145, PC-3, LnCap) for phenotype and sensitivity to adriamycin (ADR) and vinblastine (Velb) with or without the new cyclosporine A derivative PSC 833 (PSC)
129. Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug resistant solid tumors
130. Pulsed exposure of SDZ PSC 833 to multidrug resistant P388/ADR and MCF7/ADR cells in the absence of anticancer drugs can fully restore sensitivity to doxorubicin
131. Doxorubicin encapsulated in sterically stabilized liposomes exhibits renal and biliary clearance properties that are independent of valspodar (PSC 833) under conditions that significantly inhibit nonencapsulated drug excretion
132. Increased intracellular drug accumulation and complete chemosensitization achieved in multidrug-resistant solid tumors by coadministering valspodar (PSC 833) with sterically stabilized liposomal doxorubicin
133. The MRP gene associated with a non-P-glycoprotein multidrug resistance encodes a 190-kDa membrane bound glycoprotein
134. Use of etoposide in combination with cyclosporine for purging multidrug resistant leukemic cells from bone marrow in a mouse model
135. Relationship between amount of P-glycoprotein and cellular adriamycin retention in lung cancer cell lines
136. Antitumor activity of 7-Ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-c amptothecin, a novel water soluble derivative of camptothecin, against murine tumors
137. Detoxification mechanisms and tumor cell resistance to anticancer drugs
138. In vitro cardiac potencies of multidrug resistance modulators
139. Reversal of intrinsic resistance to adriamycin in normal cells by verapamil
140. Cancer statistics 1998
141. Placental p-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice
142. Differential expression of P-glycoprotein genes in primary rat hepatocyte culture
143. 4 export carrier in mastocytoma cells
144. 4 and structurally related conjugates
145. P-glycoprotein mediated transport of morphine in brain capillary endothelial cells
146. Glutathione S-transferase isoenzymes in human tumours and tumour derived cell lines
147. Reduced permeability in CHO cells as a mechanism of resistance to colchicine
148. DNA topoisomerase poisons as antitumor drugs
149. Eukaryotic DNA topoisomerases: Two forms of type I DNA topoisomerases from HeLa cell nuclei
150. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
151. p53 is required for radiation-induced apoptosis in mouse thymocytes
152. MDR expression in normal tissues: Pharmacologic implications for the clinical use of P-glycoprotein inhibitors
153. Stage-specific distribution of p-glycoprotein in first-trimester and full-term human placenta
154. Binary combinations of four protein subunits with different catalytic specificities explain the relationship between six basic glutathione S-transferases in rat liver cytosol
155. Reduction of drug accumulation and DNA topoisomerase II activity in acquired teniposide-resistant human cancer KB cell lines
156. Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice
157. Expression of the MRP gene-encoded conjugate export pump in liver and its selective absence from the canalicular membrane in transport-deficient mutant hepatocytes
158. Pharmacokinetics and antitumor activity of epirubicin encapsulated in long-circulating liposomes incorporating a polyethylene glycol-derivatized phospholipid
159. Glutathione deficiency produced by inhibition of its synthesis and its reversal: applications in research and therapy
160. Glutathione, ascorbate, and cellular protection
161. Southwest Oncology Group clinical trials of chemosensitizers in non-Hodgkin's lymphomas
162. Tumor suppressor P53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo
163. Microsomal glutathione transferase. Primary structure
164. Elevation of pi class glutathione S-transferase activity in human breast cancer cells by transfection of the GST pi gene and its effect on sensitivity to toxins
165. Randomized phase II study of single-agent epirubicin±verapamil in patients with advanced metastatic breast cancer
166. Hepatobiliary transport kinetics of HSR-903, a new quinolone antibacterial agent
167. A phase II trial of vinblastine plus dipyridamole in advanced renal cell carcinoma
168. Effects of (-)-desmethoxyverapamil on heart and vascular smooth muscle
169. MDR hamster cells exhibiting multiple altered gene expression: effects of dexniguldipine-HCl (B859-35), cyclosporine A and buthionine sulfoximine
170. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance
171. Immunohistochemical identification of P-glycoprotein in previously untreated diffuse large cell and immunoblastic lymphomas
172. Effects of verapamil on the pharmacokinetics of daunomycin in the rat
173. Site-directed mutagenesis of vicinal cysteine residues in human multidrug resistance protein, MRP
174. Topoisomerase inhibitors induce apoptosis in thymocytes
175. Biochemical basis for the interactions of type I and II topoisomerases with DNA
176. The role of canalicular multispecific organic anion transporter in the disposal of endo- and xenobiotics
177. Hepatobiliary secretion of organic compounds: molecular mechanisms of membrane transport
178. Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients
179. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy
180. A phase I trial of doxorubicin and VX-710
181. Enhancement of the activity of immunotoxins by analogues of verapamil
182. Reversal of multidrug resistance in human KB cell lines by structural analogs of verapamil
183. Verapamil reversal of clinical doxorubicin resistance in human cancer
184. P-Glycoprotein and alterations in the glutathione/glutathione-peroxidase cycle underlie doxorubicin resistance in HL-60-R, a subclone of the HL-60 human leukemia cell line
185. Mouse liver glutathione s-transferase isoenzyme activity toward aflatoxin B1-8,9-epoxide and benzo[a]pyrene-7,8-9,10-epoxide
186. Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by tamoxifen and other triparanol analogues
187. Restoration of doxorubicin responsiveness in doxorubicin-resistant P388 murine leukemia cells
188. Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance
189. Differential expression of the bcl-2 proto-oncogene in neuroblastomas and other human neural tumors
190. Purification of P-glycoprotein from plasma membrane vesicles of Chinese hamster ovary cell mutants with reduced colchicine permeability
191. Analysis of the steady-state and initial rate of doxorubicin efflux from a series of multidrug-resistant cells expressing different levels of P-glycoprotein
192. Lower electrical membrane potential and altered pHi homeostasis in multidrug-resistant (MDR) cells: further characterization of a series of MDR cell lines expressing different levels of P-glycoprotein
193. Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells
194. Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage
195. The topoisomerase II inhibitor teniposide (VM-26) induces apoptosis in unstimulated mature murine lymphocytes
196. MRP gene assessment in human cancer, normal lung, and lung cancer cell lines
197. Vinblastine photoaffinity labeling of a high molecular weight surface membrane glycoprotein specific for multidrug-resistant cells
198. Identification of the multidrug resistance-related membrane glycoprotein as an acceptor for calcium channel blockers
199. Modulation of vinblastine resistance with cyclosporine: A phase I study
200. Cyclosporin A does not reverse clinical resistance to paclitaxel in patients with relapsed non-Hodgkin's lymphoma
201. Carrier-mediated mechanism for the biliary excretion of the quinolone antibiotic grepafloxacin and its glucuronide in rats
202. Multidrug resistance associated protein gene expression in small cell and non small cell lung cancer
203. Expression of the MRP2 gene-encoded conjugate export pump in human kidney proximal tubule epithelia and in renal-cell carcinomas
204. Characterization of glutathione S-transferase expression in lymphocytes from chronic lymphocytic leukemia patients
205. Potentiation of doxorubicin cytotoxicity by the calcium antagonist bepridil in anthracycline-resistant and sensitive cell lines
206. Inhibition of vincristine binding to plasma membrane vesicles from daunorubicin-resistant Ehrlich ascites cells by multidrug resistance modulators
207. Geometric resistance to blood flow in solid tumors perfused ex vivo: effects of tumor size and perfusion pressure
208. ATPase activity of purified and reconstituted P-glycoprotein from Chinese hamster ovary cells
209. Reconstitution of drug transport by purified P-glycoprotein
210. Functional reconstitution of drug transport and ATPase activity in proteoliposomes containing partially purified P-glycoprotein
211. Chemosensitizers counteracting acquired resistance to antharacyclines and vinca alkaloids in vivo. A new resistance treatment principle
212. Verapamil restoration of daunorubicin responsiveness in daunorubicin-resistant Ehrlich ascites carcinoma
213. Cyclosporine A corrects daunorubicin resistance in Ehrlich ascites carcinoma
214. Absence or pharmacological blocking of placental p-glycoprotein profoundly increases fetal drug exposure
215. Sufficient levels of quinine in the serum circumvent the multidrug resistance of the human leukemic cell line K562/ADM
216. Quinine circumvents the doxorubicin resistance of a multidrug resistant human leukemia cell line, K562/DXR
217. Effect of the non-immunosuppressive cyclosporine analogue SDZ PSC 833 on colchicine and doxorubicin biliary secretion in the rat in vivo
218. Effect of cyclosporin on colchicine secretion by a liver canalicular transporter studied in vivo
219. Effect of cyclosporine on colchicine secretion by the kidney multidrug transporter studied in vivo
220. P-glycoprotein drug efflux pump involved in the mechanisms of intrinsic drug resistance in various colon cancer cell lines. Evidence for a saturation of active daunorubicin transport
221. Tissue distribution of p-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK-16
222. Apparent stronger expression in the human adrenal cortex than in the human adrenal medulla of Mr 170 000-180 000 P-glycoprotein
223. Nonproductive rearrangement of DNA topoisomerase I and II genes: Correlation with resistance to topoisomerase inhibitors
224. Functional involvement of p-glycoprotein in blood-brain barrier
225. Ethacrynic acid and piriprost as enhancers of cytotoxicity in drug resistant and sensitive cell lines
226. Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II
227. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II
228. Cellular localization of the multidrug resistance gene product P-glycoprotein in normal human tissues
229. Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein, P170: evidence for localization in brain capillaries and cross-reactivity of one antibody with a muscle protein
230. A phase I study of paclitaxel (T) with R-verapamil (RV) in metastatic breast cancer (MBC)
231. The reciprocal partners of both the t(14;18)and t(11;14) translocations involved in B-cell neoplasms are rearranged by the same mechanism
232. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil
233. Increased accumulation of vincristine and adriamycin in drug resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors
234. Enhancement of vincristine and adriamycin-induced cytotoxicity by verapamil in P388 leukemia and its sublines resistant to vincristine and adriamycin
235. Promotion of verapamil of vincristine responsiveness in tumor cell lines inherently resistant to the drug
236. Potentiation of vincristine and adriamycin in human hematopoietic tumor cell lines by calcium antagonists and calmodulin inhibitors
237. Circumvention of vincristine and adriamycin resistance in vitro and in vivo by calcium influx blockers
238. Effects of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and adriamycin in drug-resistant tumor cells
239. Enhanced oral bioavailability of paclitaxel in mice treated with the p-glycoprotein blocker SDZ PSC 833
240. Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A
241. The human mdr3 gene encodes a novel P-glycoprotein homologue and gives rise to alternatively spliced mRNAs in liver
242. Different effects of amiodarone, cyclosporine A and PSC 833 on mitoxantrone sensitivity in human tumor cell lines with various resistance mechanisms
243. The ABC family of multidrug transporters in microorganisms
244. The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel
245. A phase II study of epidoxorubicin in colorectal cancer and the use of cyclosporine A in an attempt to reverse multidrug resistance
246. Constitutive expression of human Bcl-2 modulates mitrogen mustard and camptothecin induced apoptosis
247. DNA topoisomerases
248. Recent studies of DNA topoisomerases
249. Modulation of multidrug resistance by SDZ PSC 833 in leukemic and solid tumor bearing mouse models
250. Comparative study on reversal efficacy of SDZ PSC 833, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo
251. Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas
252. Amplification of a gene related to mammalian mdr genes in drug-resistant Plasmodium falciparum
253. Quinidine as a resistance modulator of epirubicin in advanced breast cancer. Mature results of a placebo-controlled trial
254. The role of p-glycoprotein in blood-brain barrier transport of morphine: transcortical microdialysis studies in mdr1a (-/-) and mdr1a (+/+) mice
255. Azidopine photoaffinity labeling of multidrug resistance-associated glycoproteins
256. Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines
257. Enhanced detection of the t(14;18) translocation in malignant lymphoma using pulsed-field gel electrophoresis
258. Induction of cellular p53 activity by DNA-damaging agents and growth arrest
259. Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa)